Information  X 
Enter a valid email address

Verona Pharma PLC Ord 5P (VRP)

Date Time Source Announcement
14 Jan 2019 7:00 am
GNW
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
09 Jan 2019 1:00 pm
GNW
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17 Dec 2018 5:20 pm
GNW
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
  7:00 am
GNW
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
06 Nov 2018 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
31 Oct 2018 7:00 am
GNW
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
30 Oct 2018 6:00 am
GNW
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
26 Oct 2018 10:12 am
GNW
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
27 Sep 2018 7:00 am
GNW
Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018
20 Sep 2018 4:49 pm
GNW
Issue of Shares & PDMR Announcement
13 Sep 2018 1:00 pm
GNW
Verona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress
12 Sep 2018 7:00 am
GNW
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress
06 Sep 2018 7:00 am
GNW
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal
10 Aug 2018 12:12 pm
GNW
Verona Pharma plc : PDMR Dealing & Issue of Shares
07 Aug 2018 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
01 Aug 2018 7:00 am
GNW
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
26 Jul 2018 1:30 pm
GNW
Verona Pharma plc : Notice of Results
24 Jul 2018 1:30 pm
GNW
Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference
26 Jun 2018 5:22 pm
GNW
Verona Pharma plc : Result of General Meeting of Shareholders
04 Jun 2018 7:00 am
GNW
Verona Pharma's Shelf Registration Statement declared effective by SEC
31 May 2018 7:00 am
GNW
Verona Pharma plc : Block Listing Update
30 May 2018 1:30 pm
GNW
Verona Pharma to Present at Upcoming Investor Conferences
23 May 2018 7:00 am
GNW
Verona Pharma Files Shelf Registration Statement with SEC
22 May 2018 7:03 am
GNW
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
09 May 2018 1:30 pm
GNW
Verona Pharma plc : Miscellaneous
08 May 2018 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
04 May 2018 1:30 pm
GNW
Verona Pharma to Present at Bio€quity Europe 2018
03 May 2018 8:31 am
GNW
Verona Pharma plc : Result of AGM
02 May 2018 1:30 pm
GNW
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018
11 Apr 2018 7:00 am
GNW
Verona Pharma Announces Departure of Chief Medical Officer
26 Mar 2018 7:00 am
GNW
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
15 Mar 2018 12:00 pm
GNW
Verona Pharma to Present at Upcoming Healthcare Investor Conferences
09 Mar 2018 5:30 pm
GNW
Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGM
  2:24 pm
GNW
Verona Pharma plc : Grant of Options and RSUs and PDMR Dealings
08 Mar 2018 1:38 pm
GNW
Verona Pharma plc : 1st Quarter Results
02 Mar 2018 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  7:00 am
GNW
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients
27 Feb 2018 7:00 am
GNW
Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017
22 Feb 2018 1:45 pm
GNW
Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017
13 Feb 2018 12:35 pm
GNW
Verona Pharma Provides Clinical Development Update
30 Nov 2017 6:52 pm
GNW
Verona Pharma plc : Block listing Interim Review
  1:56 pm
GNW
Verona Pharma plc : PDMR Dealing
07 Nov 2017 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
  7:00 am
GNW
Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
31 Oct 2017 7:00 am
GNW
Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
  6:55 am
GNW
Verona Pharma to Present at Two Upcoming Investor Conferences
02 Oct 2017 7:00 am
GNW
Verona Pharma plc : Total voting rights
27 Sep 2017 7:00 am
GNW
Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients
19 Sep 2017 12:46 pm
GNW
Verona Pharma plc : Miscellaneous
07 Sep 2017 7:00 am
GNW
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
01 Sep 2017 7:00 am
GNW
Verona Pharma Appoints Stifel as Nominated Adviser
21 Aug 2017 10:41 am
GNW
PDMR Dealing
08 Aug 2017 7:00 am
GNW
Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update
02 Aug 2017 4:00 pm
GNW
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
01 Aug 2017 12:05 pm
GNW
Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference
26 Jul 2017 7:00 am
GNW
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
27 Jun 2017 7:00 am
GNW
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
22 Jun 2017 12:00 pm
GNW
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
06 Jun 2017 12:29 pm
GNW
Verona Pharma plc : Holding(s) in Company
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t